Reviewing Rein Therapeutics (RNTX) & Its Peers

Volatility and Risk

Rein Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Rein Therapeutics’ peers have a beta of 4.18, indicating that their average stock price is 318% more volatile than the S&P 500.

Profitability

This table compares Rein Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-74.08%	-27.93%
Rein Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Valuation and Earnings

This table compares Rein Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rein Therapeutics	N/A	-$15.73 million	-0.70
Rein Therapeutics Competitors	$9.91 billion	$136.15 million	-5.41

Rein Therapeutics’ peers have higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Rein Therapeutics beats its peers on 5 of the 9 factors compared.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.